The effect of dipeptidyl peptidase‐4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double‐blind, placebo‐controlled crossover study

Abstract

Vildagliptin does not alter satiation or gastric volume in people with type 2 diabetes despite elevated GLP-1 concentrations. Compensatory changes in enteroendocrine secretion could account for the lack of gastrointestinal symptoms.